A Phase 1 interventional study of Evacetrapib and Gemfibrozil in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-03.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
Drug: Gemfibrozil
Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
Drug: Evacetrapib
Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
Drug: Evacetrapib · Drug: Gemfibrozil
Also known as: LY2484595
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
| Milestone | All Participants |
|---|---|
| Started | 24 |
| Received at least one dose of study drug | 24 |
| Completed | 24 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 24 |
| Completed | 21 |
| Not completed | 3 |
| Withdrew: Adverse event | 3 |
| Milestone | All Participants |
|---|---|
| Started | 21 |
| Completed | 20 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
| nanograms/milliliter (ng/mL) | Evacetrapib | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib | 1270 ± 26 | 1290 ± 26 |
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
| nanograms*hours/milliliter (ng*h/mL) | Evacetrapib | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib | 11300 ± 20 | 11400 ± 21 |
Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.
| hours | Evacetrapib | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib | 4.00 (2.02 to 6.00) | 3.00 (2.00 to 4.00) |
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
| ng*h/mL | Gemfibrozil | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil | 55700 ± 23 | 53800 ± 22 |
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
| ng/mL | Gemfibrozil | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil | 17400 ± 32 | 16800 ± 34 |
Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.
| hours | Gemfibrozil | Evacetrapib + Gemfibrozil |
|---|---|---|
| Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil | 1.00 (1.00 to 4.00) | 1.08 (1.08 to 4.00) |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemfibrozil | — | 0/24 (0%) | 1/24 (4.2%) |
| Evacetrapib | — | 0/24 (0%) | 8/24 (33.3%) |
| Evacetrapib + Gemfibrozil | — | 0/21 (0%) | 7/21 (33.3%) |
| Event | Gemfibrozil | Evacetrapib | Evacetrapib + Gemfibrozil |
|---|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/24 | 0/24 | 2/21 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/24 | 2/24 | 0/21 |
| Ocular hyperaemiaEye disorders | 0/24 | 0/24 | 1/21 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 0/24 | 1/21 |
| Decreased appetiteMetabolism and nutrition disorders | 0/24 | 0/24 | 1/21 |
| HeadacheNervous system disorders | 0/24 | 0/24 | 1/21 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 0/24 | 0/24 | 1/21 |
| AcneSkin and subcutaneous tissue disorders | 0/24 | 0/24 | 1/21 |
| PruritusSkin and subcutaneous tissue disorders | 0/24 | 1/24 | 1/21 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 0/24 | 1/21 |
All enrolled participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 41.8 ± 10.4 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 2 |
| Male | 22 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| White | 14 |
| Black | 7 |
| Multiple | 3 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 24 |
The record gives a start of Dec 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Evacetrapib · Gemfibrozil